WINSTON-SALEM, N.C., March 22 /PRNewswire-FirstCall/ -- Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will be presenting at three upcoming investor conferences:
-- Future Leaders in the Biotech Industry Conference on Thursday, March 29, 2007 at 11:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York City. -- Leerink Swann & Company/MEDACorp Alzheimer's Disease Roundtable Conference on Tuesday, April 3, 2007 at 9:45 a.m. Eastern Time at the Le Parker Meridien Hotel in New York City. -- CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, April 11, 2007 at 9:10 a.m. Eastern Time at the Millennium Broadway Hotel in New York City. (Logo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO )
All presentations will be webcast and accessible from the Investor Relations section of the Company's website at www.targacept.com. Each webcast will also be available for replay on the Company's website for two weeks following the corresponding conference. To ensure a timely connection to a webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, as well as multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina. Targacept's news releases are available on its website at www.targacept.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGOPRN Photo Desk, photodesk@prnewswire.comTargacept, Inc.CONTACT: Alan Musso, VP and CFO of Targacept, Inc., +1-336-480-2186,alan.musso@targacept.com; or Michelle Linn, of Linnden Communications,+1-508-419-1555, linnmich@comcast.net, for Targacept, Inc.
Web site: http://www.targacept.com/
